CTLA4 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs) targeting PD-1, PD-L1 and CTLA-4 have an increasing role in the treatment of NSCLC [18,19,20,21,22,23,24,25,26,27].